LATS2 and chronic myelogenous leukemia, BCR-ABL1 positive: Based on these results, it is possible that higher levels of LATS1 and LATS2 in our IM-resistant CML patients could contribute to IM resistance by increasing proliferation and reducing apoptosis of CML cells in these patients during IM treatment.